Autoimmune diseases occur when the immune system mistakenly flags certain cells in the body as foreign invaders. The resulting attack can cause irreparable damage to critical organs and tissues. For example, in multiple sclerosis, it’s the myelin coating that insulates nerve cells; in lupus, it can be any number of organs or systems that are damaged. Currently, the primary methods to treat patients with autoimmune disease utilize immune suppressors, which help reduce the inflammatory attack on tissues but can put patients at higher risk for developing infections.
Immune tolerance therapies are designed to reprogram the immune system to stop the disease-causing immune attack on self-tissue while maintaining the immune system's ability to fight infection. The Immune Tolerance Network (ITN) is also working to identify biomarkers of immune tolerance that may help to identify the right treatment course for future patients.
This section contains a list of ITN's autoimmune clinical trials that are currently enrolling participants. To see all of ITN's active and completed studies in autoimmune disease, please visit For Researchers.
Principal Investigator:
Patrick Nachman, MD | University of Minnesota
Ignacio Sanz, MD | Emory University
REBOOT will test whether a combination of, belimumab and rituximab, is safe and if this combination is more effective at blocking the immune attack on the kidney of patients with Primary Membranous Neuropathy (MN).
Category:
Autoimmune Disease
|
Specific Category:
|
Status:
Active
Learn more:
Principal Investigator:
Jeffrey Cohen, MD | Cleveland Clinic
George Georges, MD | Fred Hutchinson Cancer Research Center
Paolo Muraro, MD, PhD | Imperial College London
BEAT-MS is a clinical trial comparing chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat relapsing MS.
Category:
Autoimmune Disease
|
Specific Category:
Multiple Sclerosis
|
Status:
Active
Learn more:
Principal Investigator:
Doruk Erkan, MD, MPH | Hospital for Special Surgery
Jason Knight, MD, PhD | University of Michigan
A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.
Category:
Autoimmune Disease
|
Specific Category:
|
Status:
Active
Learn more:
Principal Investigator:
Betty Diamond, MD | Feinstein Institute for Medical Research
David Wofsy, MD | University of California San Francisco School of Medicine
Maria Dall'Era, MD | University of California San Francisco School of Medicine
The goal of the VIBRANT trial is to determine if treating lupus nephritis with VIB4920 in addition to standard therapy is more effective than treating lupus nephritis with standard therapy alone.
Category:
Autoimmune Disease
|
Specific Category:
Lupus
|
Status:
Active
Learn more:
